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IMPORTANCE Dermatologists, pulmonologists, and rheumatologists study and treat patients
with sarcoidosis with cutaneous manifestations. The validity of cutaneous sarcoidosis
outcome instruments for use across medical specialties remains unknown.
OBJECTIVE To assess the reliability and validity of cutaneous sarcoidosis outcome
instruments for use by dermatologists and nondermatologists treating sarcoidosis.
DESIGN, SETTING, AND PARTICIPANTS Weperformed a cross-sectional study evaluating the
use of the Cutaneous Sarcoidosis Activity andMorphology Instrument (CSAMI) and
Sarcoidosis Activity and Severity Index (SASI) to assess cutaneous sarcoidosis disease severity
and the Physician’s Global Assessment (PGA) as a reference instrument. Four dermatologists,
3 pulmonologists, and 4 rheumatologists evaluated facial cutaneous sarcoidosis in 13 patients
treated at a cutaneous sarcoidosis clinic in a 1-day study on October 24, 2014; data analysis
was performed fromNovember through December 2014.
MAIN OUTCOMES ANDMEASURES Interrater and intrarater reliability and convergent validity,
with correlation with quality-of-life measures as the secondary outcome.
RESULTS All instruments demonstrated excellent intrarater reliability. Interrater reliability
(reported as intraclass correlation coefficient [95% CI]) was good for the CSAMI Activity scale
(0.69 [0.51-0.87]) and PGA (0.66 [0.47-0.85]), weak for the CSAMI Damage scale (0.26
[0.11-0.52]), and excellent for themodified Facial SASI (0.78 [0.63-0.91]). The CSAMI Activity
scale andmodified Facial SASI showedmoderate correlations (95% CI) with the PGA (0.67
[0.57-0.75] and 0.57 [0.45-0.66], respectively). The CSAMI Activity scale but not the
modified Facial SASI showed significant correlations (95% CI) with quality-of-life instruments,
such as the Dermatology Life Quality Index (Spearman rank correlation, 0.70 [0.25-0.90])
and the Skin Stigma raw score of the Sarcoidosis Assessment Tool (Pearson product moment
correlation, 0.56 [0.01-0.85]).
CONCLUSIONS AND RELEVANCE The CSAMI and SASI were reliable and valid in assessing
cutaneous sarcoidosis among our diverse group of specialists. The CSAMI Activity score also
correlated with quality-of-life measures and suggested construct validity. These results lend
credibility to expand the use of the CSAMI and SASI by dermatologists and nondermatologists
in assessing cutaneous sarcoidosis disease activity.
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S arcoidosis is an uncommon multisystem inflammatorydiseasecharacterizedbynoncaseatinggranulomatous in-filtrates,withcutaneousmanifestationsoccurring in25%
to 30% of cases.1 Although studies of treatments for cutane-
ous sarcoidosis have been based on limited observational
evidence,2 multiple randomized clinical trials on the efficacy
ofsystemictreatmentshaveemerged.3-7 Intheabsenceofastan-
dardized, validated, and widely accepted instrument to mea-
surecutaneoussarcoidosis severity,manyof theseclinical trials
useddifferent adhoc outcome instruments to assess objective
clinical severity and therapeutic end points, thus limiting the
validity of the results and comparability across trials.
Twooutcome instruments for cutaneous sarcoidosis have
undergonepsychometric validation.8,9 The SarcoidosisActiv-
ity and Severity Index (SASI)8 was the first instrument devel-
oped tomeasure cutaneousdisease severity by a groupof pul-
monologistswithexpertise in treatingsarcoidosisandhassince
been incorporated intomultiple clinical studies.5,7,8,10 TheCu-
taneous Sarcoidosis Activity and Morphology Instrument
(CSAMI)wasproposedby a groupof dermatologists ledby the
principal investigator of our study (M.R.) with experience in
treatingcutaneoussarcoidosisandwasdesignedtocapturedis-
ease activity and damage.9 Among dermatologists, both in-
struments demonstrated excellent intrarater reliability, ac-
ceptable interrater reliability, andconvergentvalidity,whereas
the CSAMI also suggested correlation with quality-of-life
measures.9 Given the multisystem nature of sarcoidosis ne-
cessitating interdisciplinary evaluation,management, and re-
search, a criterion standard outcomemeasure for the cutane-
ous manifestations of sarcoidosis should display satisfactory
psychometricproperties foruseamongvariousspecialistsman-
aging this disease, including pulmonologists, rheumatolo-
gists, anddermatologists. Toour knowledge, no studyhas ex-
amined the validity of cutaneous sarcoidosis outcome
instruments across specialists.
Our primary objectives were to assess the intrarater and
interrater reliabilitiesandconvergentvalidityof theCSAMIand
SASI in a group of pulmonologists, rheumatologists, and der-
matologists. Our secondary objective was to evaluate the in-
struments’ correlations with quality-of-life measures to ad-
dress construct validity.
Methods
The study was approved by the institutional review board of
theUniversityof Pennsylvania.Written informedconsentwas
obtained from all patients.
Physician Participants
Fourdermatologists,3pulmonologists,and4rheumatologists—
allboard-certified,attending-levelphysiciansexcept1pulmonol-
ogy fellowand1 rheumatology fellow—withexperience indiag-
nosing and managing sarcoidosis were invited to complete
this 1-day study in October 2014. All participants completed a
training session on the assessment of cutaneous sarcoidosis
usingtheCSAMI,SASI,andPhysician’sGlobalAssessment(PGA),
which constituted the 3 outcome instruments.
Patient Participants
Patients from the Cutaneous Sarcoidosis Clinic at the Hospi-
tal of the University of Pennsylvania were recruited via
telephone. All eligible patients had a clinical diagnosis of cu-
taneoussarcoidosis thatwassupportedbyhistopathologic find-
ings. Patients were selected by one of us (M.R.) to include a
range of sarcoidosis presentation and severity. However, be-
cause the SASI only evaluates sarcoidosis lesions on the face,
we limited recruitment of patient participants to those with
facial involvement.Thirteenpatientsparticipatedon thestudy
day (1 patient did not show), and all completed the following
3 self-administered surveys on the effect of cutaneous sar-
coidosisonhealth-relatedqualityof life: theSkindex-29,11Der-
matologyLifeQuality Index (DLQI),12 and Sarcoidosis Assess-
ment Tool (SAT).13
Study Design
In this cross-sectional study, physicians rated sarcoidosis
in each patient using the CSAMI, SASI, and PGA. Each
physician then rerated sarcoidosis in 2 patients with each
instrument.
Cutaneous Sarcoidosis Activity andMorphology Instrument
TheCSAMI consists of 2 separate scalesmeasuring inflamma-
tory activity and disease damage.9 The Activity scale mea-
sures inflammation, induration, and/or depression; surface
changes, such as scaling and ulceration; and area of involve-
ment. The Damage scale measures dyspigmentation and
scarring. When limited to evaluation of facial areas, CSAMI
scoresmay range from0 to 75 (maximumactivity) for the Ac-
tivity scale and 0 to 10 (maximum damage) for the Damage
scale.Morphologic types of cutaneous sarcoidosis lesions, in-
cluding the presence of lupus pernio, were also documented.
Erythema nodosum was not assessed given the focus on fa-
cial lesions.
Sarcoidosis Activity and Severity Index
TheSASImeasures erythema, induration, desquamation, and
area of involvement for each of the 4 facial quadrants and the
nose, thusproducing5 separate setsof scoresperpatient.8The
instrumenthas sincebeenmodified tobe incorporated inclini-
cal trials asasingle severity score.5,7,10ThemodifiedFacial SASI
score is calculatedby summing the erythema, induration, and
desquamationscores;multiplyingbytherespectiveareascores;
andcalculating themeanacross all 5 facial regions.9Themodi-
fied Facial SASI scores may range from 0 to 72 (maximum
activity/severity).
Physician’s Global Assessment
Atpresent, nocriterion standard instrument existswithwhich
wemayassess criterionvalidity; alternatively,weuse thePGA
to assess convergent validity, with the expectation that valid
outcome instrumentswould correlatepositivelywith thePGA
in reflecting overall physician-assessed disease severity. The
PGA used in this study is a linear visual analog scale ranging
from 0 (no evidence of disease) to 10 (extremely severe dis-
ease). The PGA has been used to rate the physician’s overall
impression of disease severity in instrument validation stud-
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ies for inflammatory skin disorders, such as dermatomyosi-
tis, pemphigus, and cutaneous sarcoidosis.9,14,15
Quality-of-LifeMetrics
TheSkindex-2911 andDLQI12arevalidatedandwidelyusedder-
matology-specific quality-of-lifemetrics. The Skindex-29 is a
29-item survey with Emotions, Symptoms, and Functioning
domains, each ranging from 0 (no effect on quality of life) to
100 (effect always experienced).11 The DLQI is a 10-item sur-
vey assessing the effect of skin diseases on the patient’s life,
with scores ranging from 0 (no effect) to 30 (extremely large
effect).12 The SAT is a novel health-related quality-of-life in-
strument developed specifically for sarcoidosis, focusing on
common issues affecting patients owing to pulmonary, oph-
thalmic, and cutaneous involvement.13,16,17 The SAThasdem-
onstrated good internal consistency and convergent validity
with the DLQI and patient-assessed global disease severity; a
minimal clinically important difference has also been
established.13 Raw sum scores were used as an alternative to
convertedscoresbasedon item-response theorymodels.16Our
study focused on the Skin Concerns and Skin Stigma scales of
the SAT tomeasure cutaneous sarcoidosis-specific quality-of-
life burden; their maximal ranges are 0 to 40 and 0 to 20, re-
spectively,withhigher scores representing greater quality-of-
lifeburden.Thesequality-of-lifemetricswereallused toassess
construct validity, with the expectation that valid disease se-
verity outcome instruments will correlate positively with pa-
tient-assessed effect of skin disease on quality of life.
Statistical Analysis
Weperformeddata analyses fromNovember throughDecem-
ber 2014. Scores from each instrument were summarized
descriptively.Weassessednormality assumptionswith skew-
ness andkurtosis tests. The reliability of each instrumentwas
analyzedusing the intraclass correlationcoefficient (ICC).18 In-
trarater and interrater reliability ICCs were calculated using
1-wayand2-way random-effectsmodels, respectively, and in-
terpreted as poor (<0.40), fair to good (0.40-0.75), and excel-
lent (>0.75).18,19 Intrarater and interrater reliabilities of CSAMI
morphologic types were analyzed using κ statistics.20,21 Con-
vergent and construct validities were assessed by comparing
the CSAMI and SASI with other physician- and patient-
reported outcomemeasures, such as the PGA and quality-of-
life surveys, using Pearson product moment correlation (r
value) or Spearman rank correlation (ρ value) as appropriate,
with bootstrap confidence intervals.22 Correlation statistics
were interpreted as slight (0-0.2), fair (>0.2 to 0.4),moderate
(>0.4 to0.6), substantial (>0.6 to0.8), andalmostperfect (>0.8)
agreement.23Weusedmixed-effects linear regression to con-
firm the linearity of the associations with the PGA, adjusting
for interrater and intrarater variations as random effects and
PGAscores as a fixedeffect. Posthoc reliability analyses strati-
fied by dermatologists and nondermatologists were per-
formed. Statistical approachwas independently reviewedand
confirmedbyabiostatisticianwhowasnot involved in the ini-
tial analysis (D.B.S.). All statisticswere analyzed using STATA
(version 12.1; StataCorp LP).We planned to include at least 12
patients with 11 physician ratings per patient to detect an in-
terrater ICCof 0.7with 80%power,when the ICC is 0.4 under
the null hypothesis, using a 2-tailed F test with a significance
level of .05.
Results
Of 22 eligible patients who were approached, 13 were avail-
able and participated in this study. Their mean (SD) age was
51.2 (10.6) years; 3 patients were male. Twelve patients were
African American and 1 patient was white. Sarcoidosis
involvement was documented in a mean (SD) of 1.7 (1.3)
extracutaneous organ systems. The patients presented with
a wide spectrum of skin disease severity as evidenced by the
range of PGA scores from 0.2 to 9.8 (Table 1). Patients’ cuta-
neous morphologic features, as determined by one of us
(M.R.), and current treatments are displayed in eTable 1 in
the Supplement.
Intrarater and Interrater Reliabilities
All 3 study instruments demonstrated excellent intrarater re-
liability. Interrater reliability (presented as ICC [95% CI]) was
good for the CSAMI Activity scale (0.69 [0.51-0.87]) and PGA
(0.66 [0.47-0.85]), weak for the CSAMI Damage scale (0.26
[0.11-0.52]), and excellent for the modified Facial SASI (0.78
[0.63-0.91]) (Table 2). Themorphologic types overall demon-
stratedsubstantial intrarater reliability (κ = 0.66 [95%CI,0.47-
0.84]) and moderate interrater reliability (κ = 0.46 [95% CI,
0.33-0.59]). Thepredominantmorphologic type selected also
showedsubstantial intrarater reliability (κ = 0.66[95%CI,0.35-
0.90]) and fair interrater reliability (κ = 0.35 [95% CI, 0.23-
0.50]). Thepresence of lupus pernio displayed substantial in-
trarater reliability (κ = 0.74 [95% CI, 0.46-1.00]) and fair
interrater reliability (κ = 0.34 [95% CI, 0.15-0.55]).
Table 1. Disease Severity Ratings of Patient Participantsa
Instrument Score, Study Range Score, Maximum Range Median Score (IQR)
CSAMI Activity scale 0-47 0-75 14 (10-18)
Inflammation 0-12 0-15 3 (2-5)
Induration and/or depression 0-12 0-15 3 (2-5)
Surface changes 0-7 0-15 1 (0-3)
Area 0-19 0-30 6 (4-8)
CSAMI Damage scale 0-10 0-10 2 (1-4)
Modified Facial SASI 0-43.2 0-72 3.2 (1.4-5.6)
PGA 0.2-9.8 0-10 3.6 (2.0-5.4)
Abbreviations: CSAMI, Cutaneous
Sarcoidosis Activity andMorphology
Instrument; IQR, interquartile range;
PGA, Physician’s Global Assessment;
SASI, Sarcoidosis Activity and
Severity Index.
a Rescored disease severity scores for
intrarater reliability analysis were
excluded for baseline descriptions.
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Convergent Validity
The CSAMI Activity scale and modified Facial SASI demon-
strated moderate correlations with the PGA (Table 2). The
CSAMI Damage scale did not correlate with the PGA. Mixed-
effects regressionmodelingalsodemonstrated that a 1-unit in-
crease in PGA score significantly predicted linear increases in
the CSAMI Activity scale (regression coefficient β, 2.42 [95%
CI, 2.03-2.80]; P < .001) andmodified Facial SASI (regression
coefficient β, 1.55 [95% CI, 1.20-1.90]; P < .001) scores.
Construct ValidityWith Quality-of-LifeMeasures
The mean (SD) Skindex-29 Emotions, Symptoms, and Func-
tioning domain scores were 65.8 (19.8), 44.6 (15.7), and 42.9
(16.7), respectively.Themean (SD)SATSkinConcernsandSkin
Stigma raw sum scores were 13.3 (11.8) and 11.1 (6.4), respec-
tively. ThemedianDLQI scorewas 2 (interquartile range, 1-7).
The CSAMI Activity scale demonstrated a strong corre-
lation with the DLQI (ρ = 0.70 [95% CI, 0.25-0.90]) and
moderate correlation with the SAT Skin Stigma raw score
(r = 0.56 [95% CI, 0.01-0.85]). Several CSAMI Activity scale
components also demonstrated significant correlations with
the Skindex-29 Functioning, DLQI, and SAT Skin Concerns
components (eTable 2 in the Supplement). The PGA demon-
strated a strong correlation with the Skindex-29 Function-
ing component (r = 0.75 [95% CI, 0.34-0.92]). The modified
Facial SASI failed to correlate with any health-related
quality-of-life measures.
Exploratory Analyses
Post hoc analyses of interrater and intrarater reliabilitieswere
performedwithstratificationbetweendermatologistsandnon-
dermatologists (Table3). Intrarater reliability for theCSAMIAc-
tivity andDamage scales,modifiedFacial SASI, andPGAwere
excellent among dermatologists and nondermatologists. In-
terrater reliability for the CSAMI Activity and Damage scales
and modified Facial SASI trended higher among dermatolo-
gists than among nondermatologists; interrater reliability for
the PGA was comparable between the 2 groups.
Discussion
This studywasunique in its inclusionofpulmonologists, rheu-
matologists, and dermatologists who treat patients with sar-
coidosis; by demonstrating reliability and convergent valid-
ity in this diverse group, our data lend credibility to expand
theuse of theCSAMI and SASI bydermatologists andnonder-
matologists in assessing cutaneous sarcoidosis disease activ-
Table 3. Exploratory Analyses on Interrater and Intrarater Reliabilities Among Dermatologists
and Nondermatologists
Instrument
Reliability, ICC (95% CI)
Intrarater Interrater
Dermatologists
(n = 4)
Nondermatologists
(n = 7)
Dermatologists
(n = 4)
Nondermatologists
(n = 7)
CSAMI Activity
scale
0.87 (0.53-0.97) 0.92 (0.77-0.97) 0.74 (0.49-0.90) 0.67 (0.46-0.86)
Inflammation 0.78 (0.27-0.95) 0.91 (0.75-0.97) 0.76 (0.55-0.90) 0.60 (0.38-0.82)
Induration
and/or
depression
0.88 (0.56-0.97) 0.85 (0.60-0.95) 0.64 (0.31-0.86) 0.57 (0.35-0.80)
Surface
changes
0.91 (0.65-0.98) 0.86 (0.64-0.95) 0.77 (0.57-0.91) 0.57 (0.34-0.80)
Area 0.71 (0.14-0.93) 0.85 (0.61-0.95) 0.58 (0.31-0.82) 0.57 (0.36-0.80)
CSAMI Damage
scale
1.00a 0.83 (0.56-0.94) 0.37 (0.12-0.68) 0.19 (0.05-0.46)
Modified Facial
SASI
0.97 (0.85-0.99) 0.99 (0.96-0.995) 0.81 (0.63-0.93) 0.74 (0.56-0.90)
PGA 0.93 (0.72-0.99) 0.86 (0.63-0.95) 0.65 (0.41-0.86) 0.66 (0.45-0.85)
Abbreviations: CSAMI, Cutaneous
Sarcoidosis Activity andMorphology
Instrument; ICC, intraclass correlation
coefficient; PGA, Physician’s Global
Assessment; SASI, Sarcoidosis
Activity and Severity Index.
a The 95% CI could not be calculated
because perfect intrarater reliability
was demonstrated.
Table 2. Intrarater and Interrater Reliabilities and Convergent Validity of Cutaneous Sarcoidosis
SeverityMeasures
Instrument
Reliability, ICC (95% CI) Spearman ρ (95% CI)
Intrarater Interrater Convergent Validity
CSAMI Activity scale 0.90 (0.77 to 0.96) 0.69 (0.51 to 0.87) 0.67 (0.57 to 0.75)
Inflammation 0.86 (0.69 to 0.94) 0.65 (0.46 to 0.84) 0.53 (0.42 to 0.64)
Induration and/or depression 0.86 (0.70 to 0.94) 0.58 (0.38 to 0.80) 0.63 (0.54 to 0.72)
Surface changes 0.88 (0.74 to 0.95) 0.61 (0.41 to 0.82) 0.42 (0.28 to 0.53)
Area 0.82 (0.62 to 0.92) 0.56 (0.37 to 0.79) 0.59 (0.48 to 0.68)
CSAMI Damage scale 0.89 (0.75 to 0.95) 0.26 (0.11 to 0.52) −0.03 (−0.19 to 0.12)
Modified Facial SASI 0.98 (0.95 to 0.99) 0.78 (0.63 to 0.91) 0.57 (0.45 to 0.66)
PGA 0.87 (0.72 to 0.95) 0.66 (0.47 to 0.85) NA
Abbreviations: CSAMI, Cutaneous
Sarcoidosis Activity andMorphology
Instrument; ICC, intraclass correlation
coefficient; NA, not applicable;
PGA, Physician’s Global Assessment;
SASI, Sarcoidosis Activity and
Severity Index.
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ity. Involvementofboth setsof specialistswill be critical in lay-
ing the foundation for large-scale, multidisciplinary,
randomized clinical trials of future treatments for sarcoidosis
with cutaneous manifestations.
Although significant reliability was demonstrated for the
CSAMI and SASI for use among our diverse group of special-
ists, interrater reliability for the instruments was noted to be
comparable to or lower than those in a prior validation study9
among dermatologists only. This result may not be surpris-
ing, given thedifferent trainingand familiarity inassessing cu-
taneous sarcoidosis severity among specialties. Although this
study was not powered to detect differences among special-
ties, exploratory analyses suggested a potential trend toward
higher interrater reliability amongdermatologists thanamong
nondermatologists. Although this trend is consistent with a
prior validation study for an outcome instrument for cutane-
ous lupus erythematosus,24 overall satisfactory reliability of
the instruments were nonetheless demonstrated among der-
matologists and nondermatologists.
Congruentwith the initial validation study, theCSAMIAc-
tivity scale and modified Facial SASI demonstrated conver-
gentvaliditywithmoderate correlationswith thePGA.9Asob-
served previously, the CSAMI Damage scale did not correlate
well with the PGA, which is expected because the CSAMI
Damagescale isdesigned tocapture residual skindamage from
priordiseaseactivity andnot currently activedisease,whereas
the PGA is generally used to measure current overall disease
activity.
An ideal outcome instrument should capture a construct
of disease characteristics that reflects not onlyphysicians’ im-
pressions of objective disease severity but also patients’ sub-
jective impressions on the effect of disease on their lives; this
combination is essential for the development of clinically rel-
evant andpatient-orientedendpoints for interventional trials
andclinical practice. Consistentwith aprior validation study,9
we demonstrated several significant correlations and trends
for modest correlations between CSAMI scales with derma-
tology-specific and cutaneous sarcoidosis–specific quality-of-
lifemetrics. In contrast, the SASI did not correlatewith any of
the quality-of-life measures. Although our study is not pow-
ered todetectmoremodest correlations,point estimatesof the
correlationsbetween theSASI andquality-of-lifemetricswere
slight to fair at most. Consistent with our findings, a large-
scaled study13with 173 patients enrolled in aphase 2 random-
ized clinical trial of 2 biological agents for treating pulmonary
and/or cutaneous sarcoidosis also failed to demonstrate
significant correlations between the SASI and SAT Skin Con-
cerns and Skin Stigma scores (ρ = 0.06 and ρ = 0.10, respec-
tively, in the patient cohort with cutaneous disease). Over-
all, our results provide additional support for the construct
validity of the CSAMI in reflecting physician- and patient-
assessed disease severity measures, which should be con-
firmed in future research.
Our small, single-center study may be limited in its gen-
eralizability to other specialists with experience inmanaging
cutaneous manifestations of sarcoidosis. Because our study
focused on the evaluation of facial lesions, the patients’ as-
sessmentofdisease impact fromfacial sarcoidosismaybe lim-
ited if influenced by nonfacial disease involvement. The use
of the CSAMI and SASI for nonfacial lesions has not been vali-
dated specifically amongnondermatologists. Inparticular, the
SASI instrument has since been modified in clinical trials to
evaluate nonfacial lesions; themodified form and its various
ad hoc–derived outcomeswill require further validation.5,7,10
Additional studies are needed for the thorough evaluation of
psychometric properties of these instruments, including their
sensitivity to change and minimal clinically important
differences.25 Instrument revisions may continue to opti-
mize their psychometric properties in quantifying cutaneous
sarcoidosis severity; for example, assessments of morpho-
logic types may be changed to an optional feature, which in
the prior study9 had demonstrated higher reliability among
only dermatologists. Recall bias may influence intrarater re-
liabilitygiventherelativelyshort timeelapsedbetweenthe first
and second ratingswithin the same day. Inclusion of trainees
may causeunderestimationof the true interrater reliability of
the CSAMI and SASI; future validation among sarcoidosis
experts fromdifferent institutionswhoactivelyengage inclini-
cal trials may further inform validity of these instruments.
Conclusions
TheCSAMI andSASIwere reliable andvalid in assessing cuta-
neoussarcoidosisamongourdiversegroupofspecialists.Given
thereliability,convergentvalidity,andevidencesupportingcor-
relationwithdermatology-specific andcutaneous sarcoidosis–
specific quality-of-lifemetrics,wepropose that theCSAMI be
used as an outcome instrument for the evaluation of cutane-
ous disease severity in future studies of sarcoidosis.
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